The early encounter of ex vivo activated CD8 T cells with tumor vasculature via IFN-γ, prior to the T cells' exposure to tumor antigens expressed on the cancer cells, may provide clues to solving the problem of antigen escape, a problem that hinders the efficacy of ACT. This evidence concerns the gene CD8A and cancer.